Noble Financial Initiates Heron Therapeutics At Buy

Noble Financial initiated coverage on shares of Heron Therapeutics

with a Buy rating. The target price for Heron Therapeutics is set to $18. Heron Therapeutics shares have declined 8.26% over the past 52 weeks, while the S&P 500 index has gained 13.56% in the same period. Heron Therapeutics' shares dropped 1.17% to close at $8.44 yesterday.